Harm Reduct J
December 9, 2025
E. K. Argyri, J. Krecké, O. C. Robinson et al.
4 citations
Practitioners who support people after psychedelic experiences report that extended difficulties can include emotional distress, existential confusion, and challenges reintegrating into daily life. Optimal support strategies involve creating a safe, non-judgmental space, providing psychoeducation, and offering ongoing integration support. The findings suggest that tailored, compassionate care is essential for helping individuals navigate post-psychedelic challenges.
Harm Reduct J
November 25, 2025
Daniel J. Kruger, Gina Mersereau, Ashley Sullivan et al.
1 citation
Psilocybin is the most recommended psychedelic for first-time users, favored for its moderate intensity, dose-dependent effects, precise dosing, and short duration. Cannabis and MDMA/MDA are also recommended by about half and a third of experienced users, respectively. Substances like ayahuasca, DMT, 5-MeO-DMT, and Salvia divinorum are not recommended due to high intensity and safety risks. Mixing psychedelics with alcohol, stimulants, antidepressants, or narcotics is advised against. Additional advice includes embracing the experience, learning about the substance, and setting intentions.
Harm Reduct J
October 3, 2025
Carissa Dutton, Emily North, Ylona Chun Tie et al.
1 citation
Psychedelic use in naturalistic settings in Australia is increasing, and while physical risks are low, psychological risks are higher in uncontrolled environments. A scoping review of 27 papers found that users employ several harm reduction strategies, categorized into three themes: before use, during the experience, and after (integration). Strategies are influenced by motivation for use, social setting, and dosage. Only four intervention-based studies were identified, highlighting a need for more evaluated interventions. Challenges include low uptake of drug checking services and low trust in government institutions. Further research should consider differing user motivations and promote benefit enhancement alongside risk reduction.